【摘要】 目的　探讨抑癌基因蛋白p16表达与甲状腺肿瘤生物学行为之间的关系。方法　采用免疫组织化学技术 (SABC法 )检测 5 0例甲状腺肿瘤中p16蛋白的表达 ,对其与甲状腺肿瘤的病理类型、组织学分级及TNM分期之间的关系进行研究。结果　p16蛋白在甲状腺腺瘤的阳性表达率 (86 7% )明显高于甲状腺癌的表达率 (4 5 7% ) ,差异有显著性 (P <0 .0 5 )。在甲状腺癌中 ,p16蛋白表达与组织分化程度有关 ,高分化者其表达水平明显高于低分化者 (6 6 7%vs 2 5 % ,P <0 .0 5 ) ,但p16蛋白表达与甲状腺癌病理类型、肿瘤大小及临床有无转移均无明显关联 (P >0 .0 5 ) ;此外 ,甲状腺癌中p5 3及bcl 2癌基因蛋白的表达与p16蛋白表达均无关联 (P >0 .0 5 )。结论　p16蛋白表达的缺失参与了甲状腺癌的发生及分化 ,但与甲状腺癌的临床进展联系不大更多还原

【Abstract】 Objective To study the relationship between the expression of p16 protein and the biological behavour of thyroid tumor. Methods The expression of p16 protein was examined in fifty cases of thyroid tumor by immunohistochemical staining technique(SABC method). The relationship between p16 protein expression and tumor size, pathological type, differention grading and clinical stage of thyroid tumors were analysed. Results In thyroid adenoma, p16 protein expression was detected in 13 out of 15 cases(86.7%); in thyroid carcinoma p16 protein was expressed only in 16 out of 35 cases(45.7%), the difference was significant(P<0.05). In thyroid carcinoma, the positive rate of p16 protein expression in well differentiated cases was significantly higher than that in poor differentiated cases(P<0.05); and the expression of p16 protein was not correlated with the pathological type, tumor size and metastasis of the cancer. Moreover, the expression of p53 and bcl 2 oncogene protein in thyroid carcinoma was also not correlated with p16 protein expression either. Conclusions Loss of expression of p16 protein may take part in pathogenesis and differentiation of thyroid carcinoma, but it seems unnecessary for the clinical progression.更多还原